Yellow Fever – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Yellow Fever – Pipeline Review, H2 2019’, provides an overview of the Yellow Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Yellow Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Yellow Fever

– The report reviews pipeline therapeutics for Yellow Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Yellow Fever therapeutics and enlists all their major and minor projects

– The report assesses Yellow Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Yellow Fever

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Yellow Fever

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bavarian Nordic A/S

BioCryst Pharmaceuticals Inc

Emergex Vaccines Ltd

Ennaid Therapeutics LLC

Fab’entech SA

iBio Inc

Imutex Ltd

Medigen Inc

Najit Technologies Inc

Sanofi Pasteur SA

Tychan Pte Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Yellow Fever - Overview

Yellow Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Yellow Fever - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Yellow Fever - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

BioCryst Pharmaceuticals Inc

Emergex Vaccines Ltd

Ennaid Therapeutics LLC

Fab’entech SA

iBio Inc

Ology Bioservices Inc

Valneva SE

Yellow Fever - Drug Profiles

EMX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galidesivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Yellow Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Yellow Fever - Dormant Projects

Yellow Fever - Product Development Milestones

Featured News & Press Releases

Sep 17, 2018: BioCryst receives additional $3.5 million to fund clinical trials of Galidesivir in Yellow Fever

Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine

Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial

Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Yellow Fever, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Yellow Fever – Pipeline by Bavarian Nordic A/S, H2 2019

Yellow Fever – Pipeline by BioCryst Pharmaceuticals Inc, H2 2019

Yellow Fever – Pipeline by Emergex Vaccines Ltd, H2 2019

Yellow Fever – Pipeline by Ennaid Therapeutics LLC, H2 2019

Yellow Fever – Pipeline by Fab’entech SA, H2 2019

Yellow Fever – Pipeline by iBio Inc, H2 2019

Yellow Fever – Pipeline by Imutex Ltd, H2 2019

Yellow Fever – Pipeline by Medigen Inc, H2 2019

Yellow Fever – Pipeline by Najit Technologies Inc, H2 2019

Yellow Fever – Pipeline by Sanofi Pasteur SA, H2 2019

Yellow Fever – Pipeline by Tychan Pte Ltd, H2 2019

Yellow Fever – Dormant Projects, H2 2019

Yellow Fever – Dormant Projects, H2 2019 (Contd..1), H2 2019

List of Figures

List of Figures

Number of Products under Development for Yellow Fever, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports